Alexa

50 Smartest Companies of the Year 2022

‘We’re a boutique firm of results-oriented Global Strategic Consultants who inspire health transformation in Medical Affairs, Public Affairs, and Operations’: Meg Heim, President of Heim Global Consulting

thesiliconreview-meg-heim-founder-heim-global-consulting-22.jpg

Healthcare consultancy has effectively become an integral part of the life science and pharmaceutical business model. Healthcare consulting is crucial since it balances patient voice and business operations in medical-related organizations. As the pharmaceutical and biotech industries transform, this lucrative field of work will become more important. Equipped with deep product knowledge and medical affairs understanding, consulting teams can become a strategic ace in an era of Big Data.

Heim Global Consulting is one such company that provides consulting leadership in the Venture Capital (VC) and Biotech space with extensive domestic & international consulting support in the Pharmaceutical, Medical Device, and Health Technology markets. Whether you’re just starting or looking to restructure, Heim has the expertise to support your team. The company’s mantra is: to analyze, identify, advise, and execute. Heim Global Consulting is on a mission to create relationships, not transactions.

Meg Heim, President of Heim Global Consulting, spoke exclusively to The Silicon Review on how her company is sharing experience and knowledge to help clients become successful while accelerating product delivery.

Interview Highlights

Q. What was the motivation behind starting Heim Global Consulting?

After many years in the Pharmaceutical and Medical Device industry as executives, launching products and devices globally, we decided to alter our direction. Now, we share our passion for helping others. Pharma, Biotech, VC, and Scientific Societies, as well as Patient Advocacy groups, all have a place in bringing innovative products to market and securing access. Heim Global Consulting benefits from a strong group of experienced pharmaceutical executives and scientific consultants who provide senior-level strategic and operational support, with knowledge across all facets of the business and lifecycle.

Q. Can you explain your services in brief?

We’re a boutique firm of results-oriented Global Strategic Consultants who inspire health transformation in Medical Affairs, Public Affairs, and Operations. As Strategists, Scientists, Advocates, and Business Executives, we thrive on sharing our experience and knowledge to help make businesses successful while accelerating product delivery. Our accelerated process is designed to build and empower life science teams while outfitting them with the tools they need to succeed. We can support growth, accelerate plans, and put teams on a solid track to success!

Q. Expertise is the first and biggest advantage of the right consultant. How do you source the right talents to maintain the quality of your services?

We have a group of highly specialized Commercial and Medical consultants, and we are word-of-mouth driven. Many of us have worked together previously and continue to connect on many outside projects, and the advantage is people like to work with other high performers. Many of us speak and provide guidance for our respective professional organizations and continue to be thought leaders in our space.

Q. Consultants do not come with guarantees, so there is always a possibility that you might not achieve the results you planned when you hired them, irrespective of the cost. How can businesses overcome this uncertainty?

We, as an organization, have all led successful launches and operations of large, medium, and biotech companies globally. On average, we have 20+ years of experience, and all have advanced degrees, MD, Ph.D., PharmD, and MBA. So while it may be a question of cost, I believe the value lies in experience and the opportunity to have a planned execution with senior people with successful experience globally. In this job market, it is hard to hire senior-level people, and it is cost-prohibitive if you are not ready for the complete utilization of an FTE. This way, you have a plan and use the right on-time services with less knowledge transfer needed from your team. It also provides the experience transfer to teammates who may not have the necessary skill sets in a particular area and to firms looking to receive guidance on bringing products to the US, acquiring products, or building their pitch decks and prep work for VC.

Q. How do you deal with the “never-ending change” in digital transformation?

Digital is a delivery system, a roadway, not a destination. Your strategy and tools should be developed with the end-user in mind. Digitalization exponentially increases the availability of data and information. So build it like every other tool in your kit and build it into the strategy.

I also feel highly regulated industries like pharma have been cautious in their approach; however, innovative mindsets and digital innovation will impact product delivery and knowledge transfer faster than any time in our history of pharma and devices.

Once more digitalization of processes reaches the Research and Development space, and with the inclusion of digital biomarkers in clinical development and prevention, digital medicine will increase and become a normalized event, providing equity and access to patients all over the globe.

Q. Do you have any new services ready to be launched?

We launched with a complete portfolio of services to be offered. Where we are seeing our biggest growth is in the advisory to VC and early-stage biotech companies. We have been able to secure Master Service Agreements (MSA) with large pharma, so now is the time to expand our footprint in those organizations. MSA’s are complex to attain, so we are humbled by the outpouring of support in the first year of our company launch.

Q. What does the future hold for your company and its customers? Are exciting things on the way?

Yes, this is an incredible time of growth. Launches and R & D were delayed due to the pandemic. With a hybrid return to work, life, and a general change in atmosphere, companies are trying to regain the lost time. Add that to a workforce shortage; boutique high-level consulting is a needed product and part of the plan to accelerate to market.

The Stalwart at the helm of Heim Global Consulting

Meg Heim is the Founder and President of Heim Global Consulting. She has a strong leadership background in Medical Affairs, External and Public Affairs, Operations and Innovative Delivery system, as well as extensive domestic & international experience in Pharmaceutical, Medical Device and Health technology markets. A versatile leader, she has a reputation and consistent record of innovation for successful partnerships with Global and Domestic Corporate, Pharmaceutical, Biotech, Government, Advocacy and Academic groups to create consensus and build programs that create healthcare transformative change. She is a results-oriented strategic thinker who deftly bridges from strategy to implementation, utilizing her superior motivational & communication skills to build and lead top-tier global and domestic teams to achieve goals.

Before founding Heim Global Consulting, Meg achieved a successful tenure at Sanofi Pharmaceuticals, where she held three roles of increasing responsibility, scope, impact, and oversight for all companies, including research and development throughout 110 countries. A critical member of the Chief Medical Office, as Global Head, Strategic Scientific Engagement Strategy, Operations and Program Management, Meg was responsible for management oversight of Global Business Unit Strategic Scientific Stakeholder Engagement, R&D, Medical CRM, and companywide Event and Congress multinational strategy. Meg also led teams that were recognized as leaders in transformation, innovation and technology.

  • 2017, The President’s award for team success
  • 2018, Global Digital and Chief Medical Office: First place hackathon

Prior to Sanofi, as Worldwide Lead, Advocacy Cardiovascular, Diabetes, Immunoscience, and Rare Genetic Diseases at Bristol Myers-Squibb, Meg facilitated BMS being recognized in three national awards related to their advocacy and research work.

Meg currently sits on the Board of Directors of Healios AG Corporation, based in Basel Switzerland with offices in US and Spain. Healios AG is a digital MedTech company that has worked with pharmaceutical companies and academic research teams in EU and US to develop and validate digital biomarkers since 2014.

Meg received her MAS/BS from Fairleigh Dickinson College and maintains an active Registered Nurse License in New Jersey.

“We benefit from a strong group of experienced pharmaceutical executives and scientific consultants that provide senior-level strategic and operational support, with knowledge across all facets of the business and lifecycle.”